US States Cut Medicaid for GLP-1 Weight-Loss Drugs Amid Rising Demand

Several US states and cities are cutting Medicaid coverage for GLP-1 weight-loss drugs like Ozempic and Wegovy amid rising demand and costs. Experts warn that the short-term financial relief may lead to higher long-term health expenses related to obesity. This decision comes as public spending on these medications has surged recently.

Read the full story at The Guardian AU→